# Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma

> **NCT04850495** · PHASE1 · SUSPENDED · sponsor: **Yazeed Sawalha** · enrollment: 38 (estimated)

## Conditions studied

- Diffuse Large B-Cell Lymphoma
- Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
- Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin Hydrochloride
- **DRUG:** Prednisone
- **BIOLOGICAL:** Rituximab
- **DRUG:** Vincristine Sulfate
- **DRUG:** Zanubrutinib

## Key facts

- **NCT ID:** NCT04850495
- **Lead sponsor:** Yazeed Sawalha
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2021-11-16
- **Primary completion:** 2026-05-15
- **Final completion:** 2026-06-15
- **Target enrollment:** 38 (ESTIMATED)
- **Why stopped:** Reached accrual limit
- **Last updated:** 2026-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04850495

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04850495, "Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04850495. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*